Marieke Griffioen

Has grant

Associate Professor

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

ORCID

Google Scholar

About

Marieke Griffioen is an Associate Professor at Leiden University Medical Center in the Netherlands. Her research focuses on acute myeloid leukemia (AML), particularly investigating genetic mutations and their implications for immunotherapy, as well as the mechanisms of T cell responses in relation to histocompatibility antigens. Recent publications include work on single-cell resolution of NPM1-mutated AML and the development of automated manufacture techniques for TCR-engineered T cells aimed at AML therapy.

Recent Grants

Grant: Close

HLA class I-restricted neoantigens encoded by recurrent mutations as therapeutic targets for acute myeloid leukemia.

Open Date: 2019-06-01

Close Date: 2023-06-01

Grant: Close

Discovery of the dominant repertoire of polymorphic targets in anti-tumor immunity after allogeneic stem cell transplantation.

Open Date: 2017-10-01

Close Date: 2021-10-01

Grant: Close

HLA class I-restricted neoantigens as targets for immunotherapy of acute myeloid leukemia

Open Date: 2017-06-01

Close Date: 2018-10-01

Grant: Close

High throughput identification of therapeutically relevant HLA class I restricted minor histocompatibility antigens

Open Date: 2011-04-01

Close Date: 2015-04-01

Grant: Close

CD4 T-cells and HLA class II minor histocompatibility antigens in anti-tumor immunity after allogeneic stem cell transplantation

Open Date: 2008-03-01

Close Date: 2012-03-01

Marieke Griffioen

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution

Ribosome profiling shows variable sensitivity to detect open reading frames for conventional and different types of cryptic T cell antigens

Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia

Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

A transcriptomic based deconvolution framework for assessing differentiation stages and drug responses of AML

DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy

Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1/2) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy

Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation

Acquisition of a Glycosylated B-Cell Receptor Drives Follicular Lymphoma Towards a Dark Zone Phenotype

An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM.

Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.

Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase.

Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing.

Collaborators (11)

Peter van Veelen

Erik van den Akker

Marcel Reinders

Peter 't Hoen

Tassilo Leo Alexander Wachsmann

Jan Wouter Drijfhout

bert van der reijden

Mirjam H.M. Heemskerk

Ferenc Scheeren

Hendrik Veelken

Susan Kloet

How do I reach out?

Meet Kite AI